Major unmet needs for patients with arthritis include new, effective interventions for the safe treatment of chronic pain, improving insurance coverage for effective evidence-based, non-pharmacologic interventions, as well as newer, targeted small molecules, biologic DMARDs, and the development and approval of Disease Modifying Osteoarthritis Drugs (DMOADs) to slow or prevent progression of osteoarthritis.